{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:22:15Z","timestamp":1785338535881,"version":"3.55.0"},"reference-count":28,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["513066"],"award-info":[{"award-number":["513066"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: The prognosis of patients with peritoneal metastases is poor. Treatment options are limited because systemically delivered chemotherapy is not usually effective in this type of disease. Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) is a recently developed alternative technology for delivering intraperitoneal chemotherapy, potentially enhancing treatment efficacy. Here, we assess the feasibility of pressurised intraperitoneal aerosolised virotherapy (PIPAV) to deliver a different class of anticancer agents, oncolytic adenoviruses, in vitro and in vivo. Methods: Adenoviral vectors expressing reporter genes green fluorescence protein (Ad5.GFP) or firefly luciferase (Ad5.Luc) were subject to pressurised aerosolisation. The ability of the virus to survive PIPAV was assessed in vitro and in vivo by monitoring reporter gene activity. Wistar rats subjected to PIPAV were assessed for any adverse procedure related events. Results: In vitro transduction assays demonstrated that Ad5 retained viability following pressurised aerosolisation and could transduce permissive cells equally effectively as non-aerosolised control vector. PIPAV was well tolerated in rats, although minimal transduction was observed following intraperitoneal administration. Conclusions: PIPAV appears viable and well tolerated, though in vivo efficacy requires further optimisation.<\/jats:p>","DOI":"10.3390\/pharmaceutics13122043","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T02:34:05Z","timestamp":1638326045000},"page":"2043","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-6464","authenticated-orcid":false,"given":"Sophia J.","family":"Tate","sequence":"first","affiliation":[{"name":"Division of Cancer and Genetics, Cardiff University, Cardiff CF14 4XN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Van de Sande","sequence":"additional","affiliation":[{"name":"Department of Human Structure and Repair, Ghent University, B-9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-4419","authenticated-orcid":false,"given":"Wim P.","family":"Ceelen","sequence":"additional","affiliation":[{"name":"Department of Human Structure and Repair, Ghent University, B-9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Torkington","sequence":"additional","affiliation":[{"name":"Department of General Surgery, University Hospital of Wales, Cardiff CF14 4XW, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-1761","authenticated-orcid":false,"given":"Alan L.","family":"Parker","sequence":"additional","affiliation":[{"name":"Division of Cancer and Genetics, Cardiff University, Cardiff CF14 4XN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3322\/caac.21277","article-title":"Looking up: Recent advances in understanding and treating peritoneal carcinomatosis","volume":"65","author":"Lambert","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","article-title":"The transport barrier in intraperitoneal therapy","volume":"288","author":"Flessner","year":"2005","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_4","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure","volume":"89","author":"Dedrick","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","article-title":"Description of a novel approach for intraperitoneal drug delivery and the related device","volume":"26","author":"Solass","year":"2012","journal-title":"Surg. Endosc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","article-title":"Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: Proof of concept","volume":"26","author":"Solass","year":"2012","journal-title":"Surg. Endosc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.addr.2020.10.015","article-title":"Intraperitoneal aerosolized drug delivery: Technology, recent developments, and future outlook","volume":"160","author":"Debbaut","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_10","first-page":"29024","article-title":"Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal Metastasis of Advanced Human Ovarian Cancer","volume":"12","author":"Shariati","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11095-019-2646-z","article-title":"High Pressure Nebulization (PIPAC) Versus Injection for the Intraperitoneal Administration of mRNA Complexes","volume":"36","author":"Shariati","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/jvi.67.10.5911-5921.1993","article-title":"Packaging capacity and stability of human adenovirus type 5 vectors","volume":"67","author":"Bett","year":"1993","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1128\/JVI.74.6.2804-2813.2000","article-title":"Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein","volume":"74","author":"Kirby","year":"2000","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.3390\/v7112923","article-title":"Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications","volume":"7","author":"Davies","year":"2015","journal-title":"Viruses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1128\/JVI.72.3.2388-2397.1998","article-title":"Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity","volume":"72","author":"Farace","year":"1998","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","article-title":"Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes","volume":"108","author":"Parker","year":"2006","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/hum.2015.015","article-title":"Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies","volume":"26","author":"Legut","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-18-1089","article-title":"Ad5NULL-A20: A Tropism-Modified, alphavbeta6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies","volume":"24","author":"Davies","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2144\/000112993","article-title":"Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function","volume":"45","author":"Stanton","year":"2008","journal-title":"BioTechniques"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27926","DOI":"10.18632\/oncotarget.8545","article-title":"Pseudotyped alphavbeta6 integrin-targeted adenovirus vectors for ovarian cancer therapies","volume":"7","author":"Davies","year":"2016","journal-title":"Oncotarget"},{"key":"ref_24","first-page":"32","article-title":"Establishment of a rat model for pressurized intraperitoneal aerosol chemotherapy","volume":"58","author":"Willaert","year":"2017","journal-title":"Eur. Surg. Res."},{"key":"ref_25","unstructured":"Uusi-Kerttula, H. (2017). Development of Ovarian Cancer-Targeted Adenoviral Vectors. [Ph.D. Thesis, Cardiff University]."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","article-title":"Intraperitoneal therapy for peritoneal tumors: Biophysics and clinical evidence","volume":"7","author":"Ceelen","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.nucmedbio.2008.03.006","article-title":"Comparison of intravenous and intraperitoneal [123I] IBZM injection for dopamine D2 receptor imaging in mice","volume":"35","author":"Meyer","year":"2008","journal-title":"Nucl. Med. Biol."},{"key":"ref_28","first-page":"3380","article-title":"Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy","volume":"49","author":"Los","year":"1989","journal-title":"Cancer Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/2043\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:37:48Z","timestamp":1760168268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/2043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["pharmaceutics13122043"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13122043","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}